Navigation Links
Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
Date:10/27/2009

BEIJING, Oct. 27 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its third purchase order for its H1N1 vaccine, PANFLU.1, from China's Ministry of Industry and Information Technology for the national stockpiling plan. Under this purchase order, Sinovac is required to produce an additional 5.19 million doses of PANFLU.1 (15ug/0.5ml) for the Chinese central government. Out of today's announced PANFLU.1 order, Sinovac is required to complete delivery of 2.89 million doses to the appointed provincial and municipal governments by the end of this year and supply the remaining 2.3 million doses for the central government stockpiling.

The latest 5.19 million dose purchase order is in addition to an initial order for 3.3 million doses and second order for 3 million doses received by Sinovac from the Ministry of Industry and Information Technology of China on September 4, 2009 and September 30, 2009, respectively, for a total of 11.49 million doses.

Separately, Sinovac also announced today that it competed and successfully won the bidding process to supply its seasonal flu vaccine, Anflu, to the Shanghai government. This marks Sinovac's entry into a new public market for its seasonal flu vaccine. The purchase plan from the Shanghai government reflects an expansion of government purchase programs for the seasonal flu vaccine. As part of the beneficial policies for citizens of Shanghai, certain Shanghai citizens will receive inoculation against influenza for free or with certain allowances.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are very proud to be supplying our H1N1 vaccine to the Chinese government and are confident that we can complete the national H1N1 vaccine stockpiling task in a timely manner. We continue to work towards our goal of providing citizens of China with affordable, international-quality vaccines. The agreement with the Shanghai Municipal Center for Disease Control and Prevention brings us closer to our goal as it opened up another important public market in China."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1, Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

    Sinovac Biotech Ltd.:
     Helen G. Yang
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
2. Sinovac to Present at 2009 UBS Global Life Sciences Conference
3. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
4. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
5. Sinovac Obtains Production License for H1N1 Vaccine
6. Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results
7. Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
8. Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials
9. Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1)
10. Sinovac Adjourns 2008 Annual General Meeting
11. Sinovac Receives Chinas First Influenza A (H1N1) Vaccine Order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... DELHI , February 8, 2016 ... Invictus Oncology Private Limited, an innovation-driven oncology company ... effective and less toxic, today announced that chairman ... Tata, has invested in the company as part ... financing round, joining existing investors Navam Capital and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Bulk food ... bulk foods at various stages of the production process. Despite frequently inspecting loose ... bulk products post packaging such as sacks of dry powders. , Mettler-Toledo Product ...
(Date:2/8/2016)... February 8, 2016 ... or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, ... its Chlamydia trachomatis (CT) test to be launched on the ... Directive (98/79/EC), the CT test is now cleared for sale ... --> The launch of the io® CT test signals ...
(Date:2/5/2016)... , Feb. 5, 2016 On Thursday, ... trusted information source for community, health and disaster services, ... will integrate to enhance care coordination and service ... the services they need and to better connect service ... care.   San Diego has ...
Breaking Biology Technology:
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
Breaking Biology News(10 mins):